RT Journal Article
T1 The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric Cases
A1 Martin‐Masot, Rafael
A1 Ortiz Pérez, Pilar
A1 Torcuato-Rubio, Encarnación
A1 Blasco Alonso, Javier
A1 Herrador-López, Marta
A1 Gallego Fernández, Carmen
A1 Navas-López, Víctor Manuel
K1 Colitis ulcerosa
AB Chronically active ulcerative colitis (UC) constitutes a challenge in an era where medical therapeutic options have increased while experience with colectomies has decreased. The change in the therapeutic paradigm of the disease means that patients with chronically active UC are being managed waiting to find their therapeutic target. We present 2 cases of children with chronically active UC who did not respond to intravenous steroids nor sequential therapy. A response was obtained with ustekinumab and tofacitinib, 2 drugs widely used in adults but still with little evidence in children. Highlighting the important role of patients and their families helped decision-making, facilitating the work of the medical team. With multidisciplinary management and close follow-up, they have been able to avoid surgery entering complete clinical remission.
PB Wiley
YR 2021
FD 2021
LK https://hdl.handle.net/10630/33986
UL https://hdl.handle.net/10630/33986
LA eng
NO Martín-Masot R, Ortiz Pérez P, Torcuato Rubio E, Blasco Alonso J, Herrador López M, Gallego Fernández C, Navas-López VM. The New Molecules Are Changing the Course of Pediatric Chronically Active Ulcerative Colitis: A Series of Pediatric Cases. JPGN Rep. 2021 Jul 12;2(3):e100.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 25 ene 2026